Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Transl Stroke Res. 2019 Aug 24;11(3):365–376. doi: 10.1007/s12975-019-00725-8

Fig. 3.

Fig. 3

Attrition in cavernous angioma models treated with BA-1049. (a) Ccm1+/−Msh2−/− models were treated with 0 (n=26), 1.0 (n=20), 10 (n=25) or 100 (n=25) mg/kg/day BA-1049 from weaning to the earliest age for the end of treatment (105 days of age). (b) Ccm3+/−Trp53−/− models were treated with 0 (n=24), 1.0 (n=22), 10 (n=18) or 100 (n=24) mg/kg/day BA-1049 from weaning to the earliest age for the end of treatment (77 days of age). Kaplan-Meier plots show no significant effect of treatment on survival compared with placebos. The log-rank (Mantel-Cox) test was used to assess for significant differences.